Universal Rapid Human Immunodeficiency Virus Screening at Delivery: A Cost-Effectiveness Analysis.
- 2018
Available online from MWHC library: 1998 - present
Conclusions: Intrapartum universal rapid HIV screening to decrease MTCT appears cost-effective in populations with high HIV incidence in the United States. Objective: To determine the cost-effectiveness of universal maternal HIV screening at time of delivery to decrease mother-to-child transmission (MTCT), by comparing the cost and quality-adjusted life years (QALYs) of universal rapid HIV screening at time of delivery to two current standards of care for prenatal HIV screening in the United States. Results: The incremental cost-effectiveness ratio for universal screening was Study Design: We conducted a cost-effectiveness analysis to compare the cost and QALY of universal intrapartum rapid HIV screening with two current standards of care: (I) opt-out rapid HIV testing limited to patients without previous third-trimester screening and (II) opt-out rapid HIV testing limited to patients without any prenatal screening. We developed a decision-tree model and performed sensitivity analyses to estimate the impact of variances in QALY, estimated lifetime medical costs, HIV prevalence, and cumulative incidence.
English
1064-7449
10.1155/2018/6024698 [doi] PMC5872626 [pmc]
*HIV Infections/di [Diagnosis] *Infectious Disease Transmission, Vertical/pc [Prevention & Control] *Mass Screening/ec [Economics] *Mass Screening/mt [Methods] Adolescent Adult Cost-Benefit Analysis Female HIV Infections/ec [Economics] Humans Incidence Middle Aged Pregnancy Prevalence Quality-Adjusted Life Years United States/ep [Epidemiology] Young Adult